Date Title
2025-01-14 Antibody-Drug Conjugates: Transforming the Biopharma Landscape
2024-12-13 Trastuzumab: Transforming the Landscape of Breast Cancer Treatment
2024-11-18 Rituximab: The First Monoclonal Antibody Approved for Cancer Treatment
2024-11-11 How Antibodies are Used in Cancer Immunotherapy
2024-10-08 Mechanisms of Action of Bispecific Antibodies in Cancer Therapy
2024-10-08 Week 2, October 2024: ADCs in Regulatory Review
2024-10-06 Antibody-Drug Conjugates and Immune Checkpoint Inhibitors in Cancer Treatment
2024-10-04 September 2024: Bispecific Antibodies in Oncology
2024-09-24 Week 4, September 2024: Anti-TIGIT Therapies
2024-09-10 Week 2, September 2024: Non-Small Cell Lung Cancer
2024-08-09 Transforming In Vivo Research with Bispecific Antibodies
2024-07-30 Week 5, July 2024: ADCs & Gynecologic Cancer
2024-07-26 Antibody-Mediated Phagocytosis Against Cancer
2024-06-28 Immune Checkpoint Inhibitors and Antibody Therapeutics: A Paradigm Shift in Cancer Treatment
2024-06-25 Week 4, June 2024: Immune Checkpoint Blockade
2024-06-14 Multi-Payload Antibody–Drug Conjugates
2024-06-04 Week 1, June 2024: Multi-Payload ADCs
2024-05-28 Week 4, May 2024: Extensive-Stage Small-Cell Lung Cancer
2024-05-24 Antibody Basics: Part 8 - Therapeutic targets - Oncology: What is cancer immunotherapy?
2024-05-18 PEGS 2024 – Boston: Highlights and Event Recap
2024-05-12 Chinese Antibody Society (CAS) Annual Conference 2024 – Boston: Event Recap
2024-05-02 Innovating Cancer Treatment: Bispecific Antibody Drug Conjugates
2024-04-17 ​AACR 2024 – San Diego: Summary and Research Highlights
2024-04-16 Week 3, Apr 2024: Bispecific ADCs
2024-04-11 Week 2, Apr 2024: Cancer Research Trends at AACR
2024-03-29 Bispecific Antibodies: Design, Development, and Therapeutic Potential
2024-03-12 Week 2, Mar 2024: The Battle Against Cancer
2024-02-07 Week 1, Feb 2024: Challenging Multiple Myeloma
2024-01-20 The Role of Antibodies in Immunotherapy
2023-10-25 Antibody Therapeutics Against Cancer

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.